Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective...
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients. During treatment, patients occasionally switch antifibrotic treatments. However,...
Alternative Titles
Full title
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4dbda5c1c00342a09b5cd06cd44651aa
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4dbda5c1c00342a09b5cd06cd44651aa
Other Identifiers
ISSN
1471-2466
E-ISSN
1471-2466
DOI
10.1186/s12890-021-01587-3
